What USP <61> and <62> Actually Test For — And Why Botanical Brands Keep Getting Surprised

Microbial contamination consistently ranks among the top three causes of dietary supplement recalls in FDA enforcement records. Yet when Midwest brands contact our Chicago receiving facility to submit botanical raw materials or finished formulas, microbiology testing is almost always the last thing discussed — a checkbox, not a strategy. The result: failing batches, frantic retests, and occasionally a 483 observation that becomes a warning letter.

Understanding what USP <61> and <62> actually measure — and why herbal matrices make them harder to run correctly than most labs will tell you — is the difference between a reliable release protocol and an expensive surprise.

USP <61> and <62> Are Not the Same Test

This sounds obvious. In practice, brands and some contract labs treat these chapters as interchangeable, which leads to test requests that are either over-scoped or dangerously incomplete.

USP <61> — Microbiological Examination of Nonsterile Products: Microbial Enumeration Tests — gives you two quantitative counts. The Total Aerobic Microbial Count (TAMC) measures colony-forming units of aerobic bacteria per gram or milliliter. The Total Combined Yeast and Mold Count (TYMC) does the same for fungi. Both use defined growth media — Soybean-Casein Digest Agar for TAMC, Sabouraud Dextrose Agar for TYMC — under controlled incubation: 30–35°C for 5 days for bacteria, 20–25°C for 5 days for fungi.

USP <62> — Tests for Specified Microorganisms — is qualitative. It answers a yes-or-no question: is a specific pathogen present or absent in a defined test portion? The five organisms covered are Salmonella spp. (absence required in 25 g), Escherichia coli (absence in 1 g for most oral products), Staphylococcus aureus, Pseudomonas aeruginosa, and bile-tolerant gram-negative bacteria.

These are fundamentally different risk signals. A batch can show a passing TAMC of 600 CFU/g — well under a ≤ 1,000 CFU/g limit — and still harbor a Salmonella positive. That’s a public health crisis requiring a recall. A batch can have an elevated TAMC of 1,800 CFU/g with a completely clean <62> profile. That’s a manufacturing problem, but an entirely different kind. Running only one and assuming you’ve covered both is a serious audit gap.

The acceptance criteria for TAMC and TYMC vary by dosage form and route of administration. Under USP <2021> (the harmonized acceptance criteria chapter), oral non-aqueous preparations — herbal capsules, tablets, and powders — must meet ≤ 1,000 CFU/g for TAMC and ≤ 100 CFU/g for TYMC. Oral aqueous preparations are tighter: ≤ 100 CFU/mL for TAMC. Oromucosal and inhalation products carry stricter limits still. If your analytical testing laboratory reports results without specifying which acceptance criteria apply to your dosage form, that’s worth a direct conversation before you sign off on the CoA.

Why Botanical Matrices Create Testing Problems Most Labs Won’t Mention

Finished synthetic pharmaceutical products start from purified or semi-purified ingredients. Dried roots, bark powders, and plant extracts don’t. They arrive carrying the full microbial load of the growing environment, the post-harvest drying process, the storage warehouse, and the transport leg from wherever they were sourced.

Water activity (aₓ) is a variable rarely discussed outside formulation circles, but it drives a significant share of TYMC failures in botanical powders. Many herbal powders look and feel dry but retain enough moisture to support fungal growth when storage conditions fluctuate. An ashwagandha root powder with aₓ above 0.6 can support mold proliferation in a sealed, opaque bag — with no visual or olfactory warning. We’ve received batches from Midwest supplement brands where TYMC failures came as a complete shock because the material looked perfectly fine on arrival.

But the bigger testing complication is matrix interference. A large subset of botanicals contain naturally antimicrobial compounds: curcuminoids in turmeric, eugenol in clove, thymol in thyme extract, carvacrol in oregano oil. Run the USP <61> enumeration test on these materials without proper neutralization, and those antimicrobial compounds suppress the growth of the very indicator organisms you’re trying to count. You’ll get a falsely low result — sometimes zero — on material that could be genuinely contaminated.

USP requires a method suitability test before results from any new matrix are considered valid. The analytical testing laboratory must demonstrate that recoveries of specified challenge organisms — Staphylococcus aureus ATCC 6538, Candida albicans ATCC 10231, and others — fall within 0.5 log₁₀ of the expected count after exposure to your specific product matrix. If recovery falls outside that range, the lab must introduce a neutralizer, adjust dilution factors, or use membrane filtration to physically separate the antimicrobial compounds from the test organisms before enumeration. It adds time and cost, which is why not every lab runs suitability on every new matrix without being asked. Ask explicitly — and request the supporting data, not just a declaration.

What 21 CFR 111 Actually Requires (and Where Brands Misread It)

Under 21 CFR Part 111 (cGMP for Dietary Supplements), the microbiology obligations span several subsections. Section 111.70 requires written specifications for microbial limits on every raw material and finished batch. Section 111.75(d) requires testing against those specifications before any finished batch ships. Subpart O requires investigation, documentation, and disposition of any out-of-specification result — with records that can withstand an FDA inspection.

None of these subsections tell you which specific limits to use. They require appropriate limits for your product type. And that’s where brands consistently run into trouble.

We routinely review specification sheets submitted to our Chicago facility where the listed TAMC limit is ≤ 10,000 CFU/g. That limit appears on many supplier CoAs and can be defensible for certain topical botanical raw materials or for bulk ingredient trade. But for an oral dietary supplement — a capsule, a tablet, a powder blended into a beverage — that limit conflicts with the USP <2021> acceptance criteria and would attract pointed questions during an FDA inspection. FDA investigators following the agency’s 2022 dietary supplement cGMP compliance program specifically evaluate whether microbial specifications are scientifically justified for the product’s intended use and consumer population.

Copying a limit from a supplier’s CoA without confirming it applies to your finished dosage form is a cGMP documentation gap. It’s also surprisingly common.

One nuance worth flagging: 21 CFR 111.75(a)(1)(i) requires identity testing of each lot of incoming dietary ingredients. Microbiology and identity are separate regulatory obligations — but brands often bundle both on the same test requisition. That’s efficient. Just make sure both are explicitly listed on the test order, and that the batch records treat them as distinct data points. Identity failures and microbiology failures trigger different documentation responses under 21 CFR 111 and shouldn’t be collapsed into a single disposition decision.

When a Batch Fails — The Right and Wrong Response

A failing USP <61> or <62> result triggers mandatory action under 21 CFR 111 Subpart O. The batch cannot ship. You document the failure, investigate the root cause, decide on disposition, and record the entire chain of decisions in the batch production record.

The temptation is to retest immediately and hope for a different number. FDA investigators see this pattern constantly, and it’s one of the observations that escalates from a 483 to a warning letter. Retesting isn’t inherently prohibited — but your SOPs must define when it’s permissible, how many retests are allowed, and how results are evaluated in aggregate. If your initial composite comes back at 4,200 CFU/g against a ≤ 1,000 CFU/g limit and a retest returns 850 CFU/g, the original failure doesn’t disappear from the record. Both results, the investigation, and the retest rationale are what an investigator will review.

Remediation options exist but have real trade-offs. Gamma irradiation or E-beam treatment can reduce viable counts in botanical raw materials, but may degrade thermolabile phytochemicals and doesn’t address the root cause. Blending a failing lot with a passing lot to bring the composite count below the limit is explicitly prohibited under 21 CFR 111 — and is one of the cleaner paths to a consent decree if discovered.

The cleanest resolution is always upstream. Pre-qualify your botanical ingredient suppliers. Require lot-specific microbiology CoAs — not product-level averages or shipment-wide certificates. Audit their drying and storage practices for botanical raw materials. And run incoming material testing before the ingredient enters your blending or encapsulation workflow, not after a finished batch has already been produced.

The microbiology chapter of your quality system is rarely where brands invest first. But it’s frequently where they spend the most when something goes wrong.

---

Written by Nour Abochama, VP Operations, Qalitex | Quality Consultant, Ayah Labs. Learn more about our team

Ship your sample to our Chicago facility — get a Qalitex CoA in 5–7 days. Contact us

Related from our network

• ISO 17025-accredited supplement microbiology testing — Qalitex Laboratories runs USP <61>/<62> microbial enumeration and pathogen testing under full ISO 17025 accreditation, with method suitability validation included for complex botanical matrices.
• Supplement testing services for US brands — From raw material identity to finished product release, Qalitex supports DSHEA-compliant quality programs for dietary supplement manufacturers nationwide.